Table 4.
The phenotypes overlapping across mouse models and diseases
| Detailed phenotypes | Diseases | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Common for 6 or more diseases | Rotarod impairment | DRPLA | HD | SBMA | SCA1 | SCA2 | SCA3 | SCA6 | SCA7 | SCA17 |
| Abnormal gait | DRPLA | HD | SBMA | SCA1 | SCA2 | SCA3 | SCA7 | SCA17 | ||
| Cell size decrease | DRPLA | HD | SBMA | SCA1 | SCA2 | SCA3 | SCA7 | SCA17 | ||
| Clasping | DRPLA | HD | SBMA | SCA1 | SCA2 | SCA3 | SCA7 | SCA17 | ||
| Ataxia | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA7 | SCA17 | |||
| Body weight loss | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA7 | SCA17 | |||
| Cell loss | HD | SBMA | SCA1 | SCA2 | SCA3 | SCA7 | SCA17 | |||
| Decreased lifespan | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA7 | SCA17 | |||
| Dendritic degeneration | DRPLA | HD | SCA1 | SCA2 | SCA3 | SCA7 | SCA17 | |||
| Diffused nuclear staining | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA7 | SCA17 | |||
| Electrophysiology alteration | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA6 | SCA7 | |||
| Gene expression alteration | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA7 | SCA17 | |||
| Motor and exploratory activity decrease | HD | SBMA | SCA1 | SCA3 | SCA6 | SCA7 | SCA17 | |||
| Nuclear inclusions | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA7 | SCA17 | |||
| Abnormal cell morphology | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA7 | ||||
| Brain volume decrease | DRPLA | HD | SBMA | SCA3 | SCA7 | SCA17 | ||||
| Brain weight loss | DRPLA | HD | SBMA | SCA1 | SCA3 | SCA17 | ||||
| Diffused cytoplasmic staining | HD | SBMA | SCA1 | SCA2 | SCA3 | SCA7 | ||||
| Kyphosis | HD | SBMA | SCA1 | SCA3 | SCA7 | SCA17 | ||||
| Seizures/evoked seizures | DRPLA | HD | SBMA | SCA3 | SCA7 | SCA17 | ||||
| Tremor | DRPLA | HD | SBMA | SCA3 | SCA7 | SCA17 | ||||
| Common for 4 or 5 diseases | Apoptosis increase | HD | SBMA | SCA3 | SCA7 | SCA17 | ||||
| Dark cell degeneration | HD | SBMA | SCA3 | SCA7 | SCA17 | |||||
| Loss of calbindin | SCA1 | SCA2 | SCA3 | SCA7 | SCA17 | |||||
| Reactive gliosis | HD | SCA1 | SCA3 | SCA7 | SCA17 | |||||
| Reduced fertility | DRPLA | HD | SBMA | SCA3 | SCA7 | |||||
| Axonal degeneration | DRPLA | HD | SBMA | SCA17 | ||||||
| Demyelination/thin myelin | HD | SBMA | SCA3 | SCA17 | ||||||
| General incoordination | DRPLA | HD | SCA1 | SCA7 | ||||||
| Grooming activity decrease | HD | SCA3 | SCA6 | SCA17 | ||||||
| Hindlimb dragging | HD | SBMA | SCA2 | SCA3 | ||||||
| Hypothalamic–pituitary–adrenal axis alteration | DRPLA | HD | SBMA | SCA3 | ||||||
| Infertility | HD | SBMA | SCA3 | SCA7 | ||||||
| Layer thickness decrease (cerebellum) | SCA1 | SCA3 | SCA7 | SCA17 | ||||||
| Motor and exploratory activity increase | DRPLA | HD | SCA1 | SCA3 | ||||||
| Muscle atrophy | HD | SBMA | SCA1 | SCA3 | ||||||
| Nuclear microaggregates | HD | SBMA | SCA7 | SCA17 | ||||||
| Simple motor learning deficit | HD | SCA1 | SCA3 | SCA7 | ||||||
The 21 “detailed phenotypes” (light gray) that are present in mouse models representing at least 6 diseases and 17 “detailed phenotypes” (dark gray) that are common for mouse models representing four or five diseases. For the number of “detailed phenotypes” in mouse models, see also Supp. Fig. 2